๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 11 Foshan 6 Guangzhou 6 Hefei 5 Chongqing 4
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing11 Foshan6 Guangzhou6 Hefei5 Chongqing4
All 39 locations
Target enrolment
to

Trials with a site in Beijing

11 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07418736Chronic Obstructive Pulmonary Disease
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2
318
Beijing
2025-12-18
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Baotou, Beijing, Changde, Changsha, Chengdu, Chongqing, Dalian, Foshan
2025-09-17
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin
2025-09-16
Recruiting
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
NCT06862206Chronic Obstructive Pulmonary Disease
AstraZeneca
Observational
1,000
Anhui, Anning, Beijing, Binzhou, Changzhou, Fenyang, Guangdong, Guangzhou
2025-07-11
Active, closed
A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06789289Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
256
Hefei, Beijing, Chongqing, Foshan, Jiangmen, Liuzhou, Yulin, Cangzhou
2025-03-17
Active, closed
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06707883Chronic Obstructive Pulmonary Disease
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
258
Chuzhou, Hefei, Huainan, Beijing, Lanzhou, Foshan, Guangzhou, Jiangmen
2024-12-31
Recruiting
Digital Therapy in Self-management of COPD Patients
NCT06776601Chronic Obstructive Pulmonary Disease
China-Japan Friendship Hospital
Not applicable
600
Beijing
2024-07-18
Recruiting
Safety and Efficacy of Endobronchial Valve for Bronchoscopic Lung Volume Reduction Surgery: a Prospective Pilot Study
NCT06349174Emphysema, Chronic Obstructive Pulmonary Disease
China-Japan Friendship Hospital
Not applicable
10
Beijing
2024-04-11
Recruiting
Establishment of Human Lung Stem Cell Proliferation System and Organoid Construction in COPD
NCT06275230Chronic Obstructive Pulmonary Disease
China-Japan Friendship Hospital
Observational
30
Beijing
2024-03-20
Active, closed
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche
Phase 3
2,000
Hefei, Beijing, Zunyi, Wuhan, Xuzhou, Pingxiang, Shanghai, Zigong
2023-06-28
Recruiting
Effects of COPD Standardized Management on COPD Exacerbation
NCT04664491Chronic Obstructive Pulmonary Disease
China-Japan Friendship Hospital
Not applicable
3,456
Beijing
2023-02-04
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

8 of the 11 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 11 studies
PhaseStudiesRecruitingShare
Not applicable3327.3%
Phase 23127.3%
Phase 33227.3%
Observational2218.2%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
China-Japan Friendship Hospital44
Sanofi22
AstraZeneca11
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.10
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.11
Hoffmann-La Roche10
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.